Are cannabinoids the same as cannabis?

No. Cannabinoids are a class of chemical compounds — some are produced by the cannabis plant (phytocannabinoids), some by the human body (endocannabinoids), and some in laboratories (synthetic cannabinoids). Cannabis is the plant; cannabinoids are one category of its chemical constituents, alongside terpenes, flavonoids, and other compounds.

Is CBD legal to buy over the counter in Australia?

A single low-dose CBD product (50 mg/day maximum, for adults 18+) received Schedule 3 (pharmacist-only) status in Australia from February 2021. However, the vast majority of CBD preparations remain Schedule 4 (prescription only) or Schedule 8. No CBD product is freely available without any professional involvement; always check the current TGA scheduling for the specific product and concentration in question.

Do terpenes affect how cannabinoids work?

Some researchers hypothesise that terpenes may interact with cannabinoid receptors or modulate cannabinoid pharmacology — this is part of the broader 'entourage effect' hypothesis. Published preclinical data exists for compounds like beta-caryophyllene (a known CB2 ligand), but robust human clinical evidence for terpene-cannabinoid interactions is limited. This is an active and genuinely interesting research area, but claims made in commercial contexts frequently outpace the published evidence.

What is the difference between Schedule 4 and Schedule 8 for cannabis products in Australia?

Under the Poisons Standard, Schedule 4 (prescription only) medicines require a valid prescription from an authorised prescriber but are not subject to additional state/territory controlled drug controls. Schedule 8 (controlled drug) preparations — which include most THC-containing medicinal cannabis products — carry additional regulatory requirements: stricter prescribing rules, quantity limits, record-keeping obligations, and, in some states, specific permit requirements. The distinction matters practically for both prescribers and patients.

Cannabinoid Science: FAQ

By Tom Whitfield · 27 June 2026 · 9 min read

Forty-seven cannabinoids identified in Cannabis sativa as of the most recent phytochemical surveys, and that number keeps climbing. I've been building the reference library for this site for a while now, and the questions our readers send in about cannabinoid science are , honestly , some of the best I get. Sharp, specific, occasionally stumping. So I've gathered the most common ones here, answered as plainly as I can, with the usual commitment to not dressing up "we don't fully know yet" as something more confident than it is.

One personal aside before we start: I was reorganising a pile of secondhand pharmacognosy texts I picked up at Bent Books on Wicks Street last month, and the contrast between what was "known" about cannabis in a 1970s monograph versus what's in current peer-reviewed literature is genuinely striking. The receptor science alone represents a complete reframing. Anyway , the questions.

The basics: what cannabinoids actually are

What is a cannabinoid?

Cannabinoids are a class of chemical compounds that interact with cannabinoid receptors in the human body and in other animals. They fall into three broad groups: phytocannabinoids (produced by plants, most notably Cannabis sativa), endocannabinoids (produced internally by the body), and synthetic cannabinoids (created in a laboratory). The word is often used loosely to mean only the plant-derived kind, but the receptor-binding definition covers all three.

What is the endocannabinoid system?

The endocannabinoid system is a cell-signalling network present throughout the body. It comprises cannabinoid receptors (primarily CB1 and CB2), the endogenous ligands that bind them; such as anandamide, and the enzymes responsible for synthesising and breaking down those ligands. Its discovery in the early 1990s followed from research into how THC produces its effects; scientists found a receptor it was binding to, then went looking for what the body produces naturally to use that receptor.

What is THC and why is it controlled?

Tetrahydrocannabinol (THC) is the principal psychoactive phytocannabinoid in cannabis. It binds with high affinity to CB1 receptors, which are expressed heavily in the central nervous system. Under Australia's Poisons Standard, THC-containing preparations sit at Schedule 8 (controlled drug) unless they meet specific low-concentration exemptions. Medicinal cannabis products above those thresholds require a prescription via the Special Access Scheme or an Authorised Prescriber arrangement under TGA regulation.

What about CBD, is it scheduled differently?

Cannabidiol (CBD) is non-intoxicating and was down-scheduled in Australia in 2021 to Schedule 4 (prescription only) for most therapeutic preparations, with a narrow Schedule 3 (pharmacist-only, low-dose) pathway for adults. Products above those thresholds, or with more than trace THC, remain Schedule 4 or Schedule 8. This is a meaningful regulatory distinction; CBD and THC are not treated identically, and the scheduling reflects that. Worth knowing before assuming any "CBD product" sits in a freely available category.

The minor cannabinoids

What is CBG?

Cannabigerol (CBG) is sometimes called the "parent" cannabinoid because its acidic precursor, CBGA, is the biosynthetic starting point from which most other phytocannabinoids are derived enzymatically in the plant. CBG itself appears in lower concentrations in most cannabis chemotypes. Research into its receptor pharmacology is ongoing; it shows affinity for both CB1 and CB2, though generally lower than THC.

What is THCV?

THCV is a propyl-chain homologue of THC, structurally similar but with a three-carbon rather than five-carbon side chain. That structural difference affects its receptor binding profile. At lower concentrations it appears to act as a CB1 antagonist in some experimental models; at higher concentrations the picture changes. It remains a Schedule 8 controlled drug in Australia regardless of these pharmacological nuances.

What are CBN, CBC, and CBDV?

CBN (cannabinol) forms primarily as a degradation product of THC through oxidation. CBC (cannabichromene) is the third most abundant phytocannabinoid in many chemotypes, biosynthesised from CBGA. CBDV (cannabidivarin) is, like THCV, a propyl homologue, this time of CBD. All three are subjects of early-stage preclinical research. All sit within Australia's scheduled medicines framework.

What about Delta-8-THC, Delta-10-THC, THCP, and HHC?

Delta-8-THC and Delta-10-THC are structural isomers of Delta-9-THC (the standard form). THCP is a recently identified homologue with a longer side chain that shows markedly higher CB1 binding affinity in preclinical assays. HHC (hexahydrocannabinol) is a hydrogenated form of THC. In Australia, the TGA has clarified that these analogue and isomer compounds fall within the scheduling of THC under the Poisons Standard; they are not in a legal grey zone here the way some international marketing implies. The short version is: if it's a THC analogue, assume it's controlled.

What are THCA and CBDA?

THCA and CBDA are the carboxylic acid precursors to THC and CBD respectively. In the fresh plant they exist primarily in acidic form; heat (decarboxylation) converts them to their neutral counterparts. THCA does not produce intoxication via the same CB1 mechanism as THC, though it remains scheduled in Australia.

Formulations and how the body processes cannabinoids

What's the difference between full-spectrum, broad-spectrum, and isolate?

A full-spectrum extract retains the full range of phytochemicals from the source plant, including THC (within legal limits for the relevant product class), other cannabinoids, terpenes, and flavonoids. A broad-spectrum extract is processed to remove or reduce THC while retaining other compounds. An isolate is a single purified compound; typically CBD, separated from everything else. Each has different implications for the entourage effect hypothesis, which proposes that multiple cannabis constituents interact in ways that differ from any single compound alone. That hypothesis is still being actively researched; the evidence base is preliminary.

Why does the route of administration matter?

Bioavailability, the proportion of a substance that reaches systemic circulation; varies significantly depending on how a cannabinoid is administered. Oral administration sends cannabinoids through the gut and liver before reaching the bloodstream, a process called first-pass metabolism. Inhalation bypasses the liver initially, producing faster onset but shorter duration. Sublingual and topical routes have their own distinct pharmacokinetic profiles. This is why the same milligram dose can produce very different effects via different routes, and why formulation science matters in medicinal cannabis research.

What are terpenes and do they matter in cannabis science?

Terpenes are a large class of aromatic hydrocarbons found across the plant kingdom, not unique to cannabis. In cannabis they contribute strongly to the scent and flavour profile of different chemotypes, and some researchers are investigating whether they may modulate cannabinoid effects via their own receptor interactions. Common cannabis terpenes include myrcene, limonene, alpha-pinene, linalool, and beta-caryophyllene. The science here is genuinely early-stage; terpene-focused claims in commercial contexts often run well ahead of what the published evidence supports. I'd hold that opinion pretty firmly.

Regulation and access in Australia

How does medicinal cannabis get approved in Australia?

The TGA oversees medicinal cannabis through two primary pathways. Products listed on the Australian Register of Therapeutic Goods (ARTG) have undergone full TGA evaluation. Products not on the ARTG can be accessed by patients via the Special Access Scheme (SAS) or through an Authorised Prescriber; a practitioner approved by the TGA to prescribe a specific unapproved product to a class of patients. Prescribers must meet TGA criteria, and products must comply with Good Manufacturing Practice (GMP) standards. This is a patient-practitioner conversation, not something to arrange independently.

What is the Poisons Standard?

The Poisons Standard (formally the Standard for the Uniform Scheduling of Medicines and Poisons) is the legislative instrument, made under the Therapeutic Goods Act 1989, that classifies medicines and poisons into schedules. Cannabis-derived substances appear across multiple schedules depending on the compound, concentration, and intended use. The TGA publishes the current Poisons Standard on its website; it is the primary reference for scheduling questions in Australia.

Can I import cannabinoid products from overseas?

Importing scheduled medicines into Australia without appropriate TGA authorisation is a criminal offence under the Therapeutic Goods Act 1989 and potentially the Criminal Code Act 1995. The fact that a product is legal in another jurisdiction, or available without prescription elsewhere, does not change its status under Australian law. The TGA's Personal Importation Scheme has specific, narrow conditions; medicinal cannabis products face additional requirements. This is not a grey area.

Odds and ends

What are CBDP, Exo-THC, CBE, and CBND?

CBDP (cannabidiphorol) and THCP were identified in a 2019 Italian study published in Scientific Reports, one of the more significant recent discoveries in phytocannabinoid chemistry. Exo-THC is a synthetic isomer used in research contexts. CBE and CBND are minor cannabinoids with limited published pharmacological data. These are firmly research-tier compounds; they have no approved clinical applications in Australia.

What about CBL and CBT?

CBL (cannabicyclol) forms in the plant through photochemical conversion of CBC; its pharmacology is poorly characterised. CBT (cannabitriol) exists as several stereoisomers and has similarly sparse published receptor data. Both appear in minor amounts in cannabis and are primarily of interest to researchers mapping the full phytochemical complexity of the plant.

Is there a glossary for all these terms?

Yes, the site's glossary covers individual cannabinoids, terpenes, regulatory terms, and related concepts. Direct links are embedded throughout the answers above. If you're starting from scratch, the endocannabinoid system entry is the right place to begin; everything else builds from there.

Sources

, Tom Whitfield, Health librarian, references & fact-checking

Common questions

Are cannabinoids the same as cannabis?: No. Cannabinoids are a class of chemical compounds — some are produced by the cannabis plant (phytocannabinoids), some by the human body (endocannabinoids), and some in laboratories (synthetic cannabinoids). Cannabis is the plant; cannabinoids are one category of its chemical constituents, alongside terpenes, flavonoids, and other compounds.
Is CBD legal to buy over the counter in Australia?: A single low-dose CBD product (50 mg/day maximum, for adults 18+) received Schedule 3 (pharmacist-only) status in Australia from February 2021. However, the vast majority of CBD preparations remain Schedule 4 (prescription only) or Schedule 8. No CBD product is freely available without any professional involvement; always check the current TGA scheduling for the specific product and concentration in question.
What does 'medicinal cannabis' mean under Australian law?: Under the TGA's framework, medicinal cannabis refers to cannabis-derived therapeutic goods supplied through approved channels — either listed on the ARTG or accessed via the Special Access Scheme or an Authorised Prescriber arrangement. The term has a specific regulatory meaning and does not describe all cannabis use. Products must meet GMP standards and be prescribed by a registered health practitioner.
Do terpenes affect how cannabinoids work?: Some researchers hypothesise that terpenes may interact with cannabinoid receptors or modulate cannabinoid pharmacology — this is part of the broader 'entourage effect' hypothesis. Published preclinical data exists for compounds like beta-caryophyllene (a known CB2 ligand), but robust human clinical evidence for terpene-cannabinoid interactions is limited. This is an active and genuinely interesting research area, but claims made in commercial contexts frequently outpace the published evidence.
What is the difference between Schedule 4 and Schedule 8 for cannabis products in Australia?: Under the Poisons Standard, Schedule 4 (prescription only) medicines require a valid prescription from an authorised prescriber but are not subject to additional state/territory controlled drug controls. Schedule 8 (controlled drug) preparations — which include most THC-containing medicinal cannabis products — carry additional regulatory requirements: stricter prescribing rules, quantity limits, record-keeping obligations, and, in some states, specific permit requirements. The distinction matters practically for both prescribers and patients.